Poly(ADP-ribose) Polymerase 1 Deficiency Attenuates Amyloid Pathology, Neurodegeneration, and Cognitive Decline in a...

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Poly(ADP-ribose) polymerase-1 (PARP1) is involved in DNA damage and neuroinflammation in Alzheimer's disease (AD).
• The specific role of PARP1 in amyloid-β (Aβ) pathology in AD is not fully understood.

Purpose of the Study:

• To investigate the role of PARP1 activation in driving Aβ pathology and neurodegeneration in Alzheimer's disease.
• To explore PARP1 as a potential therapeutic target for AD.

Main Methods:

• ELISA to measure PAR levels in cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD.
• In vitro studies using oligomeric Aβ1-42 to activate PARP1 and assess neuroprotection via genetic or pharmacological inhibition.
• In vivo studies using PARP1 knockout in 5XFAD mouse models of amyloidosis.

Main Results:

• Elevated PAR levels were observed in the CSF of MCI and AD patients.
• Aβ1-42 activated PARP1, induced DNA damage, and PARP1 inhibition provided neuroprotection in vitro.
• PARP1 knockout in 5XFAD mice reduced amyloid plaques, preserved neuronal integrity, attenuated neuroinflammation, and rescued cognitive deficits.
• PARP1 deficiency altered APP processing, BACE1 levels, γ-secretase composition, and enhanced Aβ degradation.

Conclusions:

• PARP1 activation is a critical mediator of Aβ toxicity and neurodegeneration in Alzheimer's disease.
• Inhibition of PARP1 represents a promising therapeutic strategy for AD, targeting both Aβ pathology and neuroinflammation.